Coherus Oncology (CHRS) FCF Margin (2013 - 2026)
Coherus Oncology (CHRS) reported FCF Margin of 470.24% for Q1 2026, down 6827.0% on a YoY basis from 6.99% in Q1 2025, and down 113.39% sequentially from 220.36% in Q4 2025.
Coherus Oncology (CHRS) FCF Margin (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 13 years of FCF Margin data on file, last reported at 470.24% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 6827.0% year-over-year to 470.24%; the trailing twelve-month figure through Mar 2026 stood at 649.38% (up 53644.0% YoY), and the FY2025 full-year result was 786.76%, up 89.0% from the prior year.
- FCF Margin declined to 470.24% in Q1 2026, from 220.36% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 6111.66% in Q1 2024 to a low of 1024.72% in Q3 2024.
- A 5-year average of 491.02% and a median of 84.65% in 2022 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin soared 632402 bps in 2024 and plunged 651362 bps in 2025, its largest moves.
- Tracing CHRS's FCF Margin over 5 years: stood at 220.59% in 2022, then surged by 94 bps to 14.17% in 2023, then surged by 2710 bps to 369.95% in 2024, then tumbled by 160 bps to 220.36% in 2025, then sank by 113 bps to 470.24% in 2026.
- Business Quant data shows CHRS's FCF Margin at 470.24% in Q1 2026, 220.36% in Q4 2025, and 400.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -470.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -470.24% |
| Dec 31, 2025 | -220.36% |
| Sep 30, 2025 | -400.48% |
| Jun 30, 2025 | 4,259.49% |
| Mar 31, 2025 | -401.96% |
| Dec 31, 2024 | 369.95% |
| Sep 30, 2024 | -1,024.72% |
| Jun 30, 2024 | 968.67% |
| Mar 31, 2024 | 6,111.66% |
| Dec 31, 2023 | -14.17% |
| Sep 30, 2023 | -72.82% |
| Jun 30, 2023 | -66.45% |
| Mar 31, 2023 | -212.37% |
| Dec 31, 2022 | -220.59% |
| Sep 30, 2022 | -82.66% |
| Jun 30, 2022 | -84.65% |
| Mar 31, 2022 | -90.93% |
| Dec 31, 2021 | -71.97% |
| Sep 30, 2021 | 16.30% |
| Jun 30, 2021 | -0.69% |